JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

A 3 1/2-year experience with double-lumen implants in breast surgery.

The use of the double-lumen implant, with 20 mg of Solu-Medrol or less, has improved the final results in patients having reconstruction after mastectomy. However, the results in patients having augmentation mammaplasties have been much more dramatic, with far superior results over those patients having a gel implant. During the first year the incidence of scar tissue problems is 17 times greater with the gel implants than with the double-lumen implants and 20 mg or less of Solu-Medrol. Scar capsules were also extremely amenable to closed capsulotomy after augmentation with the double-lumen implant, in marked contrast to the gel implant. There is no evidence to support the hypothesis that the double-lumen implant and Solu-Medrol merely delays the eventual appearance of the scar tissue problem. The recommended dosage of Solu-Medrol would appear to be 20 mg and not less.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app